Cisplatin |
| Catalog No.GC11908 |
Sample solution is provided at 25 µL, 10mM.
- 1. Xu, Xiaotian, et al. "Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis." European Journal of Pharmaceutical Sciences (2020): 105450. PMID:32621966
- 2. Li, Xiaomei, et al. "Sinomenine hydrochloride suppresses the stemness of breast cancer stem cells by inhibiting Wnt signaling pathway through down-regulation of WNT10B." Pharmacological Research (2022): 106222. PMID:35413424
Quality Control & SDS
- View current batch:
-
Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
L1210/0 cells |
|
Preparation method |
The solubility of this compound in DMF is >12.5 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. |
|
Reaction Conditions |
0, 0.5, 1, 2, 4 and 8 μg/mL; 2 hrs |
|
Applications |
At low concentrations, Cisplatin induced minimal cell death. At higher concentrations, cell death was obvious with only 4% viability. By 10 days after incubation, these few survivors begun to grow and became the predominant cells in the population. |
| Animal experiment [2]: | |
|
Animal models |
Nude mice bearing human ovarian cancer OVCAR-3 cell xenografts |
|
Dosage form |
5 mg/kg, i.v.; at day 0 and day 7 |
|
Applications |
Cisplatin (5 mg/kg) given at the day 0 and 7 induced a tumor growth inhibition (GI) (85.1%) of the OVCAR-3 cell xenografts. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 1988 Aug 15;48(16):4484-8. [2]. Molthoff CF, Pinedo HM, Schlüper HM, Rutgers DH, Boven E. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Int J Cancer. 1992 Apr 22;51(1):108-15. |
|
Cisplatin is a highly effective and broad-spectrum chemotherapeutic agent [1].
Cisplatin is an anticancer agent with some side effects. It is believed to induce apoptosis through several mechanisms. The traditional mechanism is that cisplatin enters the cell, interacts with the DNA guanine bases and forms the inter- or intra-strand chain cross-linking, then prevents the replication of DNA. This formation can also induce apoptosis by activating p53. Cisplatin was also found to cause ROS generation and increase lipid peroxidation, which leads cells to the apoptotic pathway. In addition, cisplatin induces apoptosis with the caspase-dependent pathway. In cochlear cells, cisplatin treatment results in the increase of caspases-3 and -9 and causes the cochlear damage side effect [1].
References:
[1] Casares C, Ramírez-Camacho R, Trinidad A, et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. European Archives of Oto-Rhino-Laryngology, 2012, 269(12): 2455-2459.
| Cas No. | 15663-27-1 | SDF | |
| Synonyms | CDDP | ||
| Chemical Name | azane;dichloroplatinum(2+) | ||
| Canonical SMILES | N.N.Cl[Pt+2]Cl | ||
| Formula | Cl2H6N2Pt | M.Wt | 300.05 |
| Solubility | 5 mg/mL in DMF (16.66 mM; DMSO can inactivate Cisplatin's activity), 1 mg/mL in H2O (3.33 mM; DMSO can inactivate Cisplatin's activity) | Storage | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.